V. I. Technologies, Inc.

V.I. Technologies, Inc. is a leader in the rapidly emerging field of pathogen inactivation of blood products used in blood transfusion. VITEX's technologies are designed to address the risks of viral contamination of blood products, including plasma, plasma derivatives, red blood cells and platelets. Viral inactivation technologies have the potential to eliminate viruses that are enveloped by lipid membranes such as hepatitis B, hepatitis C and HIV, the virus that causes AIDS, and non-enveloped viruses such as hepatitis A virus and parvovirus and other known and unknown pathogens. The Company, in 1998, received approval from the FDA for the first virally inactivated blood product, PLAS+ŪSD. Approval to market PLAS+ŪSD in Canada was received in 1999. In July of 1999, VITEX signed a definitive agreement to merge with Pentose Pharmaceuticals of Cambridge, MA. The merger expands VITEX technology portfolio to include the Pentose INACTINE technology. In pre-clinical studies the proprietary INACTINE compounds has been shown to inactivate all classes of virus known to contaminate blood-derived products while preserving the product's key therapeutic properties. In September of 1999, Pentose received clearance from the FDA to enter clinical trials for Inactine-treated red blood cells. Red Blood Cells are the blood component most commonly used in blood transfusions.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Technology

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: